Cullinan Therapeutics, Inc. (CGEM)
10.28
+0.09
(+0.88%)
USD |
NASDAQ |
Nov 13, 16:00
10.26
-0.02
(-0.19%)
After-Hours: 19:59
Cullinan Therapeutics Enterprise Value : 381.27M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 381.27M |
| November 12, 2026 | 375.41M |
| November 11, 2026 | 450.88M |
| November 10, 2026 | 443.08M |
| November 09, 2026 | 475.61M |
| November 06, 2026 | 448.28M |
| November 05, 2026 | 415.10M |
| November 04, 2026 | 525.06M |
| November 03, 2026 | 737.16M |
| November 02, 2026 | 683.81M |
| October 30, 2026 | 690.31M |
| October 29, 2026 | 717.64M |
| October 28, 2026 | 724.80M |
| October 27, 2026 | 677.95M |
| October 26, 2026 | 658.43M |
| October 23, 2026 | 647.37M |
| October 22, 2026 | 683.16M |
| October 21, 2026 | 681.20M |
| October 20, 2026 | 677.30M |
| October 19, 2026 | 622.00M |
| October 16, 2026 | 553.68M |
| October 15, 2026 | 623.30M |
| October 14, 2026 | 599.88M |
| October 13, 2026 | 629.81M |
| October 12, 2026 | 685.11M |
| Date | Value |
|---|---|
| October 09, 2026 | 722.84M |
| October 08, 2026 | 718.29M |
| October 07, 2026 | 729.35M |
| October 06, 2026 | 769.69M |
| October 05, 2026 | 756.03M |
| October 02, 2026 | 721.54M |
| October 01, 2026 | 657.78M |
| September 30, 2026 | 711.13M |
| September 29, 2026 | 650.63M |
| September 28, 2026 | 632.56M |
| September 25, 2026 | 623.52M |
| September 24, 2026 | 664.18M |
| September 23, 2026 | 756.49M |
| September 22, 2026 | 1.066B |
| September 21, 2026 | 1.046B |
| September 18, 2026 | 1.028B |
| September 17, 2026 | 1.046B |
| September 16, 2026 | 999.20M |
| September 15, 2026 | 993.39M |
| September 14, 2026 | 984.35M |
| September 11, 2026 | 996.62M |
| September 10, 2026 | 1.023B |
| September 09, 2026 | 1.043B |
| September 08, 2026 | 1.068B |
| September 04, 2026 | 1.093B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Climb Bio, Inc. | 393.71M |
| Oncolytics Biotech, Inc. | 42.45M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 1.897B |
| Anixa Biosciences, Inc. | 75.65M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.39M |
| Total Expenses (Quarterly) | 49.39M |
| EPS Diluted (Quarterly) | -0.7645 |
| Earnings Yield | -32.12% |
| Normalized Earnings Yield | -32.12 |